SCHEMBL295886

SCHEMBL295886

COC(=O)[C@H](CS)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
CTSK P43235 9/20 0.45
CTSS P25774 6/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CTSL P07711 2/20 0.43
CTSB P07858 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KLK5 Q9Y337 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CA12 O43570 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3819517 1.00 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1341495 1.00 CYP1A2 (0.46) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7079252 0.91 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL6237621 0.91 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL9039507 0.89 CTSK (0.42) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL9037870 0.89 CTSK (0.42) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL370241 0.88 KMT2A (0.43) CTSKCTSSCA1CA2CA7
SCHEMBL28948917 0.88 KMT2A (0.43) CTSKCTSSCA1CA2CA7
SCHEMBL28948914 0.87 CTSL (0.56) CTSKCTSSCA1CA2CA7
SCHEMBL26818450 0.87 CTSL (0.56) CTSKCTSSCA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252477-A1 NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF UNIVERSITA' DEGLI STUDI DI TORINO (60%) (IT) 2024-08-01 US claimed
CN-116162255-B Charge-convertible dendrimer and preparation method thereof 东莞理工学院 2024-07-09 CN claimed
CN-117867481-A High-stability cyanide-free electroless reduced gold plating solution 江苏矽智半导体科技有限公司 2024-04-12 CN claimed
EP-4334287-A1 NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF Università Degli Studi Di Torino (IT) 2024-03-13 EP claimed
CN-116789579-A Preparation method of ultrafast metal-free solvent-free disulfide bond-containing compound 南京工业大学 2023-09-22 CN claimed
CN-116162255-A Charge-convertible dendrimer and preparation method thereof 东莞理工学院 2023-05-26 CN claimed
WO-2022234447-A1 NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF UNIVERSITA' DEGLI STUDI DI TORINO (IT) 2022-11-10 WO claimed
CN-103852511-B Electrophoresis-mediated microanalysis determination method for chiral separation of arginine in pharmaceutical preparation 上海市食品药品检验所 2018-05-22 CN claimed
US-20030077059-A1 Optical fiber coating compositions CORNING INCORPORATED 2003-04-24 US claimed
US-RE50899-E1 Small diameter low attenuation optical fiber CORNING INCORPORATED (US) 2026-05-26 US disclosed
US-12486241-B2 Cystine diamide analogs for cystinuria RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-12-02 US disclosed
US-12479933-B2 Crosslinked alginic acid structure MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2025-11-25 US disclosed
US-12377164-B2 Linkers and conjugates ASTRAZENECA AB (SE) 2025-08-05 US disclosed
EP-4587029-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES Invea Therapeutics, Inc. (US) 2025-07-23 EP disclosed
US-6284910-B1 FARNESYL TRANSFERASE INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2001-09-04 US disclosed
US-6268339-B1 Lanthionine bridged peptides Kolbeck, Winfried (DE) 2001-07-31 US disclosed
US-6046235-A SULFUR-CONTAINING AMINO ACID DERIVATIVES WHICH HAVE INHIBITORY EFFECTS ON LEUKOTRIENE A4 HYDROLASE AND USEFUL AS THERAPEUTICAL AGENTS FOR INFLAMMATORY DISEASES SUCH AS RHEUMATISM, PSORIASIS, GOUT, CYSTIC FIBROSIS AND BOWL DISEASES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2000-04-04 US disclosed
US-6028168-A Lanthionine bridged peptides WINFRIED KOLBECK (DE) 2000-02-22 US disclosed
EP-0947502-A1 NOVEL SULFUR-CONTAINING AMINO ACID DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed
US-5874549-A A METABOLIZABLE BICYCLIC, NON-AROMATIC HYDROCARBON COMPOUND TO A FREE CARBOXYL GROUP, ACID-CLEAVABLY LINKS AN AMIDE-CONTAINING ACTIVE AGENT TO A TARGETING AGENT FOR USE AS DRUG DELIVERY, DRUG CARRIER NEORX CORPORATION (US) 1999-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486241-B2 Cystine diamide analogs for cystinuria CTH, CBS, SLC7A11 CYP1A2 4197/4885CYP2C9 3077/4885CYP2C19 3402/4885
US-20240252477-A1 NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF NLRP3, PYCARD, NLRP1 CYP1A2 1481/4885CYP2C9 3588/4885CYP2C19 3279/4885
US-12377164-B2 Linkers and conjugates F13A1, NGLY1, SPPL2A CYP1A2 4213/4885CYP2C9 4477/4885CYP2C19 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.